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RESULTS  
 
 
• Prepared genomic libraries of 7 MDR strains were 
sequenced on Roche 454 GS FLX Titanium NGS 
platform at the Centre for Life Sciences, NLA-NU.  
• FastQC was applied to analyze reads quality and 
adapters were trimmed using Trimmomatic v.0.38 to 
truncate low quality reads.  
• De novo assembling has been performed by 
Velvet v.1.2.10.  
• Gene prediction and annotation were carried out 
with Genome Annotation Service PATRIC, using RAST 
toolkit.  
• High quality reads were then mapped to the 
M.tuberculosis H37Rv genome (GenBank 
AL123456.3) using GS Reference Mapper v.2.8. The 
alignments files were subjected to local realignment 
and de-duplication using GS Reference Mapper v.2.8 
and MUMmer v.3.23. Identified genomic variants 
were annotated using in-house prepared Python 
script.  
• Comparative phylogenetic analysis has been 
performed by Maximum-Likelihood method based 
on Tamura-Nei model in MEGA X. 
MATERIALS AND METHODS 
 
 
 
1. WHO. World health statistics, 
http://www.who.int/gho/publications/world_health_statistics/2018/en/; 2018. 
2. Ministry of Health Republic of Kazakhstan. Statistic TB review (Editor Sh. Ismailov). National 
TB Center, Almaty, 2009, 2011 (in Russian). 
3. Filliol I, Motiwala AS, Cavatore M, et al. Global phylogeny of Mycobacterium tuberculosis 
based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis 
evolution, phylogenetic accuracy of other DNA fingerprinting systems, and 
recommendations for a minimal standard SNP set. J Bacteriol 2006;188(2):759e72. 
4. 454 Sequencing System Software Manual Version 2.6. Part C:  GS De Novo Assembler, GS 
Reference Mapper, SFF Tools. 454 Life Sciences Corp. 2011 
5. World Health Organization. 2017. Global tuberculosis report 2017. World Health 
Organization, Geneva, Switzerland.  
6. Ministry of Healthcare and Social Development of the Republic of Kazakhstan. 2014. 
Statistic TB review. Ministry of Healthcare and Social Development of the Republic of 
Kazakhstan, Almaty, Kazakhstan. (In Russian.) 
7. Kozhamkulov U, Akhmetova A, Rakhimova S, Belova E, Alenova A, Bismilda V, Chingissova L, 
Ismailov S, Ramanculov E, Momynaliev K. 2011. Molecular characterization of rifampicin- 
and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Kazakhstan. Jpn J 
Infect Dis 64:253–255.  
8. Hillemann D, Kubica T, Agzamova R, Venera B, Rüsch-Gerdes S, Niemann S. 2005. 
Rifampicin and isoniazid resistance mutations in Mycobacterium tuberculosis strains 
isolated from patients in Kazakhstan. Int J Tuberc Lung Dis 9:1161–1167.  
9. Kairov U. et al. Draft Genome Sequences of Two Clinical Isolates of Mycobacterium 
tuberculosis from Sputum of Kazakh Patients. Genome Announcements. 2015 May-Jun; 
3(3): e00466-15. 
 
REFERENCES 
Figure 3. Summary of Mycobacterium tuberculosis sequencing and assembly data for 
MDR-1280 isolate. Concentric circles show the different features of isolate. From top 
to bottom – Position Lable (Mbp), Contigs (deep blue), CDS – forward strand (green), 
CDS – reverse strand (violet), Non-CDS Features (turquois), AMR Genes (red), VF Genes 
(orange), Transporters (blue), Drug Targets (black), GC Content (GC Skew). 
 
Tuberculosis remains one of the major problems 
in public health (1). During the last 10 years the 
tuberculosis incidence and mortality rate in 
Kazakhstan decreased by 2.4 times and 6 times, 
respectively. Despite the decreasing rate of 
incidences in Kazakhstan last years, the rate of 
multidrug-resistant (MDR) forms is increasing.  
 
 
 
 
 
 
 
 
 
 
 
According to WHO European Region report, 
Kazakhstan is 1 of 18 countries with a high rate of 
MDR tuberculosis (2). Some previous studies have 
been performed in Kazakhstan using genotyping and 
sequencing methods (3-5). 
It is extremely important to examine sensitive 
and resistant strains with different mutations in 
genes encoding drug metabolism among 
M.tuberculosis strains from the different geographic 
regions. 
INTRODUCTION 
  
Figure 1. Estimated incidence of MDR/RR-TB in 2016, for 
countries with at least 1000 incident cases 
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Isolate fields Drug Resistance Analysis 
Microbiology Confirmed by 
analysis genotype 
Sample ID Isolate ID AMK EMB INH OFX PZA RIF SM KM CM     
MTB-1280 1280 -/S/- R/R/R R/R/R -/S/S -/-/R R/R/R -/R/S -/S/- -/S/- MDR MDR 
MTB-1405 1405 -/S/- R/R/R R/R/R -/S/S R/-/- R/R/R R/R/R -/S/- -/S/- MDR MDR 
MTB-1524 1524 -/S/- R/R/R R/R/R -/S/S R/-/- R/R/R R/R/R -/S/- -/S/- MDR  MDR 
MTB-1525 1525 -/S/- R/R/R -/R/R -/S/S R/-/- R/R/R R/R/R -/S/- -/S/- MDR MDR 
MTB-1577 1577 -/S/- R/R/R R/R/R -/S/S R/-/R R/R/R R/R/R -/S/- -/S/- MDR MDR 
MTB-1585 1585 R/R/R R/S/R R/R/R -/S/S -/-/ R/R/R R/R/R R/R/- R/R/- MDR MDR 
MTB-1713 1713 -/S/- R/R/R R/R/R -/S/S R/-/- R/R/R R/R/R -/S/- -/S/- MDR MDR 
Isolate 
ID 
Total raw 
Paired Read  
Contigs N50 
Completion 
(%) 
Full length 
(bp) 
Coverage 
(×) 
SNPs* Indels* GC (%) Genes 
1280 195,048,344 136 90951 97.14 4 287 916  51 × 1952 225 65.46 4385 
1405 126,653,863 189 50264 96.99 4 281 841 34 × 1888 235 65.44 4414 
1524 160,749,277 166 51640 96.94 4 280 264 43 × 1908 213 65.44 4417 
1525 118,335,745 213 37986 96.80 4 273 127 31 × 1827 254 65.44 4460 
1577 120,396,884 215 44245 96.91 4 278 038 33 × 1876 239 65.44 4475 
1585 85,923,603 404 18929 96.20 4 246 265 23 × 1581 297 65.40 4623 
1713 113,788,645 250 35572 96.76 4 271 719 31 × 1763 251 65.44 4516 
Table 1. Genome assembling  statistics of M.tuberculosis isolates 
Table 2. Drug resistance profiling of Mycobacterium tuberculosis isolates 
AMK - amikacin, EMB - ethambutol, INH - isoniazid, OFX - ofloxacin, PZA - pyrazinamide, RIF - rifampin, SM - streptomycin, KM - kanamycin, CM – capreomycin 
*The number of SNPs and Indels are assessed relative to H37Rv. 
 
We performed comprehensive bioinformatics 
analysis of whole-genome data from 7 MDR isolates. 
We identified genomic variants (SNPs and InDels) in 
de novo assembled and annotated whole-genomes 
and specific/novel variants in drug-resistant genes of 
MDR strains circulated in  Kazakhstan.  
These findings may provide additional source 
for justification of drug sensitivity before clinical 
treatment as well as the basis for expansion of the 
current reference MTB database with genetic 
variability among different drug sensitivity isolates. 
Moreover, these results may provide supplementary 
information in further fundamental investigation of 
virulence and transmissibility patterns of MDR 
strains.  
 
 
CONCLUSION 
Table 3. Annotation of known and unknown genetic variants in 
antimicrobial resistance genes by ResFinder. 
 1 isoniazid, 2 rifampicin, 3 ethambutol, 4 pyrazinamide, 5 streptomycin,                                    
6 fluoroquinolones, 7 amikacin, 8 capreomycin, 9 kanamycin 
Isolate 
Drug Known target: Amino 
Acid Mutation 
Unknown target: Amino 
 Acid Mutation 
MTB-MDR-KZ (1280) INH 1 katG: S315T katG: R463L 
  RIF 2 rpoB: S450L   
  EMB 3 embB: M306V   
      thyA: P253A 
      gyrA: E21Q, S95T, G668D 
      rpoC: E1092D 
      ethA: T314I 
      kasA: K34Q 
MTB-MDR-KZ (1405) INH 1 katG: S315T katG: R463L 
  PZA 4 pncA: G24D   
  SM 5 rpsL: K43R   
  FLQ 6 gyrB: D461N gyrA: E21Q, S95T, G668D 
  RIF 2 rpoB: S450L rpoB: H723D, rpoC: E1092D 
  EMB 3 embB: M306V   
MTB-MDR-KZ (1524) INH 1 katG: S315T katG: R463L 
  PZA 4 pncA: L182S pncA: R176C, T177A, A178P, S179P, 
V180A, E181S, V183W, C184F, 
S185A, S186A 
  SM 5 rpsL: K43R   
  RIF 2 rpoB: S450L rpoC: E1092D 
  EMB 3 embB: M306V   
      thyA: P253A 
      gyrA: E21Q, S95T, G668D 
      ethA: T314I 
MTB-MDR-KZ (1525) INH 1 katG: S315T katG: R463L 
  PZA 4 pncA: T76P   
  SM 5 rpsL: K43R   
  RIF 2 rpoB: S450L rpoC: E1092D 
  EMB 3 embB: M306V   
      thyA: P253A 
      gyrA: E21Q, S95T, G668D 
      ethA: T314I 
MTB-MDR-KZ (1577) INH 1 katG: S315T katG: R463L 
  PZA 4 pncA: promoter n.-11   
  SM 5 rpsL: K43R   
  RIF 2 rpoB: S450L   
  EMB 3 embB: M306V   
      thyA: P253A 
      gyrA: E21Q, S95T, G668D 
MTB-MDR-KZ (1585)  INH 1 katG: S315T katG: R463L 
  SM 5 rpsL: K43R   
  AMK 7,      
CM 8, 
KM 9 
rrs: 1401   
  RIF 2 rpoB: S450L rpoC: N698S, E1092D 
  EMB 3 embB: M306V   
      pncA: V155M 
      rpsA: M432T 
      thyA: P253A 
      gyrA: E21Q, S95T, G668D 
      ethA: T314I 
MTB-MDR-KZ (1713)  INH 1 katG: S315T katG: R463L 
  PZA 4 pncA: T76P   
  SM 5 rpsL: K43R   
  RIF 2 rpoB: S450L 
  EMB 3 embB: M306V   
      thyA: P253A 
      fabG1: E76E – Frameshift, E77S, 
H78T, Q79R, G80V, P81R, V82S, 
E83R,  V84C, L85W, V86C, S87P, 
N88T, A89P 
By closely examining the correlation of the phenotypic drug 
susceptibility profiles of the strains with mutations identified in 
their drug resistance-associated genes, we identified a few 
potential new genetic determinants of drug resistance. For 
example,  one isolate (MTB-1405) had gyrB D461N mutation 
known to confer resistance to fluoroquinolones according to 
ResFinder DB. But, from the other hand all  7 MDR isolates 
annotated by 3 DBs as susceptible strains. In our 7 MDR isolates 
we found unknown/novel genetic variants in gene gyrA (E21Q, 
G668D, and S95T) that can be potential determinants of 
susceptibility to fluoroquinolones among MDR strains. Results of 
drug resistance profiling among investigated 7 MDR isolates and 
identified known/unknown genetic variants in antimicrobial 
resistance genes have been shown in Table 2 and 3. 
The whole-genome sequencing for 7 MDR isolates produced 
667,052,381 paired reads with average read length 520 bp. The 
mean coverage ranged between 21-51X, and the mapping quality 
94.43-97.14%. From 4385 to 4475 coding sequences CDSs and 44 
tRNAs, 4 rRNA have been identified. Number of SNPs and InDels 
ranging from 1581 to 1952, and from 213 to 297, respectively (Table 
1). Spoligotyping analysis based on NGS data revealed all MDR 
strains as Beijing genotype. Phylogenetic analysis (based on rpoB 
gene) of the five MDR strains in comparison with seven 
susceptible/drug-resistant strains (H37Ra, H37Rv, KZN 4207, 
CDC1551 and other) has been showed clustering on two main 
clusters (Figure 2). Among all isolates we detected several new 
genetic variants in drug-resistance genes which are not 
described/unknown in antibiotic resistance databases (ResFinder 
v.3.0; CARD; CASTB). Circular maps for each MDR isolate have been 
created (Figure 3 – representation of circular map for isolate MDR-
1280). 
Figure 2. Phylogenetic tree showing the relationships of 7 isolates of 
M. tuberculosis with other Mycobacterium species based on aligned 
sequences of the rpoB gene. 
